Summary by Moomoo AI
Ming Kand Pharmaceuticals (Stock Code: 2359) issued an Overseas Regulatory Notice on 18 March 2024, mentioning that the Company's Board of Directors has assessed the independence of independent directors. The evaluators included the independent directors Lu Shaohua, Yu Wei, Zhang Xin, Zhan Zhi Ling and Feng Dai. A review of the independent directors' resumes and self-examination reports confirms that they have not held any positions in the company other than as an independent director, a member of a special committee of the Board of Directors, and that there is no interest or other relationship between the company and its actual controller or other relationship that may affect its independent objective judgment. Pursuant to legal regulations such as the Ordinance on the Management of Independent Directors of Listed Companies and the Code of Conduct on Self-Governance of Listed Companies No. 1 - Standard Operations, the Board of Directors of the Company confirms that all acting independent directors comply with the relevant independence requirements.